At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 98 enrolled
Drug / intervention
Liarozoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg od and 150 mg od) Given During 12 Weeks in Lamellar Ichthyosis
In Brief
A Phase 3 clinical trial evaluating Liarozole for Ichthyosis, Lamellar. Completed, enrolled 98 participants across 16 sites in 9 countries.
Detailed Summary
Lamellar ichthyosis is a congenital disease of the skin with a generalized scaling. The primary activity of liarozole is considered to be the inhibition of the degradation of a substance called retinoic acid, which is the principal endogenous regulator of growth and differentiation of epithelial tissues in mammals. The current study intends to evaluate the efficacy and safety in patients with lamellar ichthyosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIchthyosis, Lamellar
CountriesBelgium, Canada, Dominican Republic, France, Germany, Italy, Netherlands, Norway, Sweden
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedJan 2006
Primary CompletionApr 2007
TodayJul 2026
First PostedJan 27, 2006
Enrollment StartJan 1, 2006
Primary CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.4 years ago
Interventions
Liarozoledrug